Connect with us

Headlines

Novartis Paid $465M for Eyecare Company

mm

Published

on

The deal closed Jan. 20.

Novartis paid $465 million for Encore Vision Inc., a privately held company in Fort Worth, TX, reports DallasNews.com.

The acqusition was announced in December. It closed on Jan. 20, according to a document filed with the U.S. Securities and Exchange Commission.

The price tag was not made public in the December announcement.

Encore is developing an eye drop treatment for presbyopia.

Advertisement

Novartis, parent company of Alcon, said in the SEC filing that the preliminary fair value of the deal was $465 million.

The amount included an initial cash payment of $375 million “before ordinary purchase price adjustments” along with $90 million that would go to shareholders. Shareholders are eligible to receive the $90 million “upon achievement of specified development and commercialization milestones.” 

Read more at DallasNews.com

Advertisement

SPONSORED VIDEO

SPONSORED BY ESSILOR

Ray-Ban® Authentic

Introducing the perfect match of Ray-Ban's legendary style and Essilor's Expertise in sight. Click here for more information.

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular